Procter & Gamble Health Ltd (PGHL) Q1 FY27 Results Analysis: Revenue Growth Slows to 7.4%, Margin Pressure Persists
Procter & Gamble Health Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 363.71 Cr (+7.37% YoY) and PAT growth of +45.29% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 06, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 363.71 Cr (+7.37% YoY) |
| PAT (Q1) | Rs. 96.15 Cr (+45.29% YoY) |
| EBITDA margin | 27.38% (+71 bps YoY) |
| EPS (Q1) | Rs. 57.92 (+45.30% YoY) |
| Market cap | Rs. 10,072.51 Cr |
| CMP | Rs. 6,068.00 |
Quarter Snapshot
PGHL's Q1 FY27 revenue growth slowed to 7.4% YoY, down from the mid-to-high teens pace of recent quarters, as raw material cost inflation significantly pressured margins. Operating leverage helped EBITDA grow faster than revenue, but normalized PAT rose only 9.5% after excluding a one-time exceptional gain. The high dividend payout provides shareholder return, but lack of forward guidance and decelerating growth temper the outlook.
Key Investment Insights
Key Positives
- Revenue grew 7.37% YoY to Rs.363.71 Cr.
- EBITDA (before exceptional) grew 10.25% YoY to Rs.99.60 Cr, with margin expanding 71 bps to 27.38%.
- Reported PAT grew 45.29% YoY to Rs.96.15 Cr, though inflated by exceptional gain.
- Proposed final dividend of Rs.45 per share, total FY26 dividend of Rs.205 per share.
- Company has no borrowings and negligible finance costs.
Risk Factors
- Revenue growth decelerated to 7.37% YoY from ~19% in Q4 FY26 and ~16% in FY26.
- Raw material costs surged 34.88% YoY, expanding share of revenue by 450 bps, pressuring margins.
- Employee costs rose 18.74% QoQ and other expenses rose 17.96% QoQ, indicating internal cost pressures.
- Exceptional gain of Rs.31.80 Cr distorts reported PAT; normalized PAT grew only 9.5% YoY.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.